Literature DB >> 24954536

KRAS and YAP1 converge to regulate EMT and tumor survival.

Diane D Shao1, Wen Xue2, Elsa B Krall1, Arjun Bhutkar2, Federica Piccioni3, Xiaoxing Wang1, Anna C Schinzel1, Sabina Sood2, Joseph Rosenbluh1, Jong W Kim1, Yaara Zwang1, Thomas M Roberts4, David E Root3, Tyler Jacks5, William C Hahn6.   

Abstract

Cancer cells that express oncogenic alleles of RAS typically require sustained expression of the mutant allele for survival, but the molecular basis of this oncogene dependency remains incompletely understood. To identify genes that can functionally substitute for oncogenic RAS, we systematically expressed 15,294 open reading frames in a human KRAS-dependent colon cancer cell line engineered to express an inducible KRAS-specific shRNA. We found 147 genes that promoted survival upon KRAS suppression. In particular, the transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. Acquired resistance to Kras suppression in a Kras-driven murine lung cancer model also involved increased YAP1 signaling. KRAS and YAP1 converge on the transcription factor FOS and activate a transcriptional program involved in regulating the epithelial-mesenchymal transition (EMT). Together, these findings implicate transcriptional regulation of EMT by YAP1 as a significant component of oncogenic RAS signaling.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24954536      PMCID: PMC4110062          DOI: 10.1016/j.cell.2014.06.004

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  61 in total

Review 1.  The Sp-family of transcription factors.

Authors:  G Suske
Journal:  Gene       Date:  1999-10-01       Impact factor: 3.688

2.  TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm.

Authors:  A Vassilev; K J Kaneko; H Shu; Y Zhao; M L DePamphilis
Journal:  Genes Dev       Date:  2001-05-15       Impact factor: 11.361

3.  Improved statistical methods for hit selection in high-throughput screening.

Authors:  Christine Brideau; Bert Gunter; Bill Pikounis; Andy Liaw
Journal:  J Biomol Screen       Date:  2003-12

4.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

5.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.

Authors:  G H Fisher; S L Wellen; D Klimstra; J M Lenczowski; J W Tichelaar; M J Lizak; J A Whitsett; A Koretsky; H E Varmus
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

6.  Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.

Authors:  Y Wang; V N Ngo; M Marani; Y Yang; G Wright; L M Staudt; J Downward
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

7.  The prognostic significance of epithelial-mesenchymal transition in breast cancer.

Authors:  Ilka B Fuchs; Werner Lichtenegger; Helmut Buehler; Wolfgang Henrich; Harald Stein; Anke Kleine-Tebbe; Gerhard Schaller
Journal:  Anticancer Res       Date:  2002 Nov-Dec       Impact factor: 2.480

8.  TransFind--predicting transcriptional regulators for gene sets.

Authors:  Szymon M Kiełbasa; Holger Klein; Helge G Roider; Martin Vingron; Nils Blüthgen
Journal:  Nucleic Acids Res       Date:  2010-05-28       Impact factor: 16.971

9.  Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of beta-catenin and upregulation of beta-catenin/lymphoid enhancer binding factor-1 transcriptional activity.

Authors:  A Eger; A Stockinger; B Schaffhauser; H Beug; R Foisner
Journal:  J Cell Biol       Date:  2000-01-10       Impact factor: 10.539

10.  Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.

Authors:  M D To; R D Rosario; P M K Westcott; K L Banta; A Balmain
Journal:  Oncogene       Date:  2012-09-03       Impact factor: 9.867

View more
  337 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

Review 2.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

3.  YAP promotes epithelial mesenchymal transition by upregulating Slug expression in human colorectal cancer cells.

Authors:  Dan Cheng; Lan Jin; Yunhe Chen; Xueyan Xi; Yang Guo
Journal:  Int J Clin Exp Pathol       Date:  2020-04-01

4.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

5.  The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.

Authors:  Luping Lin; Amit J Sabnis; Elton Chan; Victor Olivas; Lindsay Cade; Evangelos Pazarentzos; Saurabh Asthana; Dana Neel; Jenny Jiacheng Yan; Xinyuan Lu; Luu Pham; Mingxue M Wang; Niki Karachaliou; Maria Gonzalez Cao; Jose Luis Manzano; Jose Luis Ramirez; Jose Miguel Sanchez Torres; Fiamma Buttitta; Charles M Rudin; Eric A Collisson; Alain Algazi; Eric Robinson; Iman Osman; Eva Muñoz-Couselo; Javier Cortes; Dennie T Frederick; Zachary A Cooper; Martin McMahon; Antonio Marchetti; Rafael Rosell; Keith T Flaherty; Jennifer A Wargo; Trever G Bivona
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

6.  The dynamic mechanism of RASSF5 and MST kinase activation by Ras.

Authors:  Tsung-Jen Liao; Hyunbum Jang; Chung-Jung Tsai; David Fushman; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2017-03-01       Impact factor: 3.676

7.  Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Authors:  Vidyalakshmi Sethunath; Huizhong Hu; Carmine De Angelis; Jamunarani Veeraraghavan; Lanfang Qin; Nicholas Wang; Lukas M Simon; Tao Wang; Xiaoyong Fu; Agostina Nardone; Resel Pereira; Sarmistha Nanda; Obi L Griffith; Anna Tsimelzon; Chad Shaw; Gary C Chamness; Jorge S Reis-Filho; Britta Weigelt; Laura M Heiser; Susan G Hilsenbeck; Shixia Huang; Mothaffar F Rimawi; Joe W Gray; C Kent Osborne; Rachel Schiff
Journal:  Mol Cancer Res       Date:  2019-08-16       Impact factor: 5.852

8.  YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.

Authors:  Bo Tu; Jun Yao; Sammy Ferri-Borgogno; Jun Zhao; Shujuan Chen; Qiuyun Wang; Liang Yan; Xin Zhou; Cihui Zhu; Seungmin Bang; Qing Chang; Christopher A Bristow; Ya'an Kang; Hongwu Zheng; Huamin Wang; Jason B Fleming; Michael Kim; Timothy P Heffernan; Giulio F Draetta; Duojia Pan; Anirban Maitra; Wantong Yao; Sonal Gupta; Haoqiang Ying
Journal:  JCI Insight       Date:  2019-11-01

9.  Circular RNA Vav3 sponges gga-miR-375 to promote epithelial-mesenchymal transition.

Authors:  Xinheng Zhang; Yiming Yan; Wencheng Lin; Aijun Li; Huanmin Zhang; Xiaoya Lei; Zhenkai Dai; Xinjian Li; Hongxin Li; Weiguo Chen; Feng Chen; Jingyun Ma; Qingmei Xie
Journal:  RNA Biol       Date:  2019-01-15       Impact factor: 4.652

10.  YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.

Authors:  Xuhao Ni; Jinhui Tao; Joseph Barbi; Qian Chen; Benjamin V Park; Zhiguang Li; Nailing Zhang; Andriana Lebid; Anjali Ramaswamy; Ping Wei; Ying Zheng; Xuehong Zhang; Xingmei Wu; Paolo Vignali; Cui-Ping Yang; Huabin Li; Drew Pardoll; Ling Lu; Duojia Pan; Fan Pan
Journal:  Cancer Discov       Date:  2018-06-15       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.